CL2018003662A1 - Formulación farmacéutica líquida estable. - Google Patents

Formulación farmacéutica líquida estable.

Info

Publication number
CL2018003662A1
CL2018003662A1 CL2018003662A CL2018003662A CL2018003662A1 CL 2018003662 A1 CL2018003662 A1 CL 2018003662A1 CL 2018003662 A CL2018003662 A CL 2018003662A CL 2018003662 A CL2018003662 A CL 2018003662A CL 2018003662 A1 CL2018003662 A1 CL 2018003662A1
Authority
CL
Chile
Prior art keywords
pharmaceutical formulation
liquid pharmaceutical
stable liquid
antibody
stability
Prior art date
Application number
CL2018003662A
Other languages
English (en)
Inventor
Joon Won Lee
Won Yong Han
Su Jung Kim
Jun Seok Oh
So Young Kim
Su Hyeon Hong
Yeon Kyeong Shin
Original Assignee
Celltrion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60787364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2018003662(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celltrion Inc filed Critical Celltrion Inc
Publication of CL2018003662A1 publication Critical patent/CL2018003662A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA UNA FORMULACIÓN FARMACÉUTICA LÍQUIDA ESTABLE QUE CONTIENE: UN ANTICUERPO O SU FRAGMENTO DE UNIÓN A ANTÍGENO; UN TENSIOACTIVO; UN AZÚCAR O SU DERIVADO; Y UN TAMPÓN. LA FORMULACIÓN FARMACÉUTICA LÍQUIDA ESTABLE DE ACUERDO CON LA PRESENTE INVENCIÓN TIENE BAJA VISCOSIDAD A LA VEZ QUE CONTIENE UN CONTENIDO ELEVADO DEL ANTICUERPO, TIENE UNA ESTABILIDAD DURANTE EL ALMACENAMIENTO A LARGO PLAZO EXCELENTE BASÁNDOSE EN LA ESTABILIDAD EXCELENTE EN CONDICIONES ACELERADAS Y CONDICIONES SEVERAS, Y SE PUEDE ADMINISTRAR POR VÍA SUBCUTÁNEA.
CL2018003662A 2016-06-30 2018-12-18 Formulación farmacéutica líquida estable. CL2018003662A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20160083039 2016-06-30

Publications (1)

Publication Number Publication Date
CL2018003662A1 true CL2018003662A1 (es) 2019-03-15

Family

ID=60787364

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003662A CL2018003662A1 (es) 2016-06-30 2018-12-18 Formulación farmacéutica líquida estable.

Country Status (40)

Country Link
US (3) US11951207B2 (es)
EP (2) EP4338752A3 (es)
JP (2) JP7082070B2 (es)
KR (3) KR20180003452A (es)
CN (1) CN109310628A (es)
AU (2) AU2017287743C1 (es)
CA (1) CA3028238C (es)
CL (1) CL2018003662A1 (es)
CO (1) CO2018013689A2 (es)
CR (1) CR20180599A (es)
CU (1) CU24561B1 (es)
DK (1) DK3479819T5 (es)
DO (1) DOP2018000290A (es)
EA (1) EA201892653A1 (es)
EC (1) ECSP18093651A (es)
ES (1) ES2975782T3 (es)
FI (1) FI3479819T3 (es)
GE (1) GEP20217249B (es)
HR (1) HRP20240426T1 (es)
HU (1) HUE066142T2 (es)
IL (1) IL263630B2 (es)
JO (1) JOP20180125B1 (es)
LT (1) LT3479819T (es)
MA (1) MA45562B1 (es)
MD (1) MD3479819T2 (es)
MX (1) MX2018015960A (es)
NI (1) NI201800139A (es)
PE (1) PE20190448A1 (es)
PH (1) PH12018502670B1 (es)
PL (1) PL3479819T3 (es)
PT (1) PT3479819T (es)
RS (1) RS65395B1 (es)
SG (1) SG11201811320YA (es)
SI (1) SI3479819T1 (es)
SM (1) SMT202400143T1 (es)
TN (1) TN2018000443A1 (es)
TW (1) TWI736643B (es)
UA (1) UA122610C2 (es)
WO (1) WO2018004260A1 (es)
ZA (1) ZA201808476B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
JP7177777B2 (ja) * 2017-01-11 2022-11-24 セルトリオン， インク． 安定した液体製剤
KR20190024572A (ko) * 2017-08-30 2019-03-08 (주)셀트리온 TNFα 관련 질환을 치료하기 위한 피하 투여 요법
WO2020060192A1 (ko) * 2018-09-18 2020-03-26 삼성바이오에피스 주식회사 고농도의 계면활성제를 포함하는 트라스투주맙 안정화 액체 제제
CA3115747A1 (en) * 2018-10-10 2020-04-16 Astellas Pharma Inc. Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
AR118191A1 (es) * 2019-02-28 2021-09-22 Celltrion Inc MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa
CN111686247B (zh) * 2019-03-13 2022-07-29 苏州康乃德生物医药有限公司 包含人白介素-4受体α的抗体的液体组合物
CN113727730A (zh) * 2019-03-18 2021-11-30 阿尔沃科技Hf公司 高浓度TNFα抗体的含水制剂
TWI878289B (zh) * 2019-04-23 2025-04-01 法商賽諾菲公司 抗ｃｄ３８抗體和調配物
CN110095615A (zh) * 2019-05-27 2019-08-06 山东艾科达生物科技有限公司 一种测定超敏c反应蛋白含量的试剂盒
CN110585430B (zh) * 2019-09-29 2023-09-08 华博生物医药技术（上海）有限公司 一种人源化抗人il-17a单克隆抗体的药物组合物
EP4119161A4 (en) * 2020-03-13 2024-05-15 Samsung Bioepis Co., Ltd. Liquid pharmaceutical composition having improved stability
PE20230116A1 (es) * 2020-04-06 2023-01-27 Univ Leland Stanford Junior Formulacion de anticuerpos
BR112022024296A2 (pt) * 2020-05-29 2023-04-25 Amgen Inc Formulações de anticorpos e seus usos
CN114099424B (zh) * 2020-08-25 2025-03-14 越海百奥药业(绍兴)有限公司 一种重组免疫细胞因子的制剂
WO2023043232A1 (ko) * 2021-09-16 2023-03-23 주식회사 에이프로젠 항-TNFα 항체를 포함하는 약제학적 조성물
CN113940997B (zh) * 2021-12-21 2022-04-08 迈威(上海)生物科技股份有限公司 一种双特异性抗体的稳定制剂
WO2023125483A1 (zh) * 2021-12-28 2023-07-06 山东先声生物制药有限公司 一种抗tnfr2抗体药物组合物
EP4630056A2 (en) * 2022-12-09 2025-10-15 Xentria, Inc. Methods of treating sarcoidosis with a tnf-a antibody and associated compositions and methods

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861335A (en) 1985-07-26 1989-08-29 Duoject Medical Systems Inc. Syringe
US5085642A (en) 1989-07-17 1992-02-04 Survival Technology, Inc. Conveniently carried frequent use autoinjector
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5681291A (en) 1992-11-19 1997-10-28 Tebro S.A. Disposable auto-injector for prefilled syringes
DE4438360C2 (de) 1994-10-27 1999-05-20 Schott Glas Vorfüllbare partikelarme, sterile Einmalspritze für die Injektion von Präparaten und Verfahren zu ihrer Herstellung
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ZA200710109B (en) * 2005-06-07 2009-10-28 Esbatech Ag Stable and soluble antibodies inhibiting TNFALPHA
LT3216803T (lt) 2008-06-25 2020-06-10 Novartis Ag Stabilūs ir tirpūs antikūnai, slopinantys vegf
MX2011011772A (es) 2009-05-04 2012-02-08 Abbott Biotech Ltd Formulaicones estables de anticuerpos humanos anti-tnf-alfa con alta concentracion de proteina.
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AU2013212587B2 (en) * 2012-01-23 2017-07-20 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-Ang2 antibodies
CA2864539C (en) * 2012-02-16 2022-06-07 Santarus, Inc. Antibody formulations
WO2013164837A1 (en) 2012-03-07 2013-11-07 Cadila Healthcare Limited Pharmaceutical formulations of tnf-alpha antibodies
US20150150982A1 (en) 2012-06-12 2015-06-04 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
WO2014039903A2 (en) 2012-09-07 2014-03-13 Coherus Biosciences, Inc. Stable aqueous formulations of adalimumab
FR2995214B1 (fr) 2012-09-10 2014-11-21 Adocia Solution a viscosite reduite de proteine a concentration elevee
EP2906599B1 (en) * 2012-10-12 2019-07-17 Agency For Science, Technology And Research Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics
US20150239970A1 (en) * 2012-10-25 2015-08-27 Medimmune, Llc Stable, Low Viscosity Antibody Formulation
WO2014078866A2 (en) * 2012-11-19 2014-05-22 Xencor, Inc. Engineered immunoglobulins with extended in vivo half-life
CA2898262A1 (en) 2013-01-24 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Tnf-alpha antigen-binding proteins
WO2015057910A1 (en) 2013-10-16 2015-04-23 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
CN104666242B (zh) 2013-11-26 2018-01-02 信达生物制药(苏州)有限公司 一种稳定的抗TNF‑α抗体制剂及其用途
CN104707146B (zh) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
IN2014MU01248A (es) * 2014-04-02 2015-10-09 Intas Pharmaceuticals Ltd
EP3050557A1 (en) * 2014-05-23 2016-08-03 Ares Trading S.A. Liquid pharmaceutical composition
HUP1400510A1 (hu) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
EP3237000A1 (en) 2014-12-23 2017-11-01 Pfizer Inc Stable aqueous antibody formulation for anti tnf alpha antibodies
EP3256160A1 (en) * 2015-02-13 2017-12-20 Sanofi Stable liquid formulation for monoclonal antibodies
AR118191A1 (es) 2019-02-28 2021-09-22 Celltrion Inc MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa

Also Published As

Publication number Publication date
AU2017287743C1 (en) 2020-10-01
CR20180599A (es) 2019-04-09
ECSP18093651A (es) 2019-01-31
EP3479819A1 (en) 2019-05-08
EP4338752A3 (en) 2024-04-03
US20240269069A1 (en) 2024-08-15
JP2022122941A (ja) 2022-08-23
DOP2018000290A (es) 2019-02-15
TWI736643B (zh) 2021-08-21
ES2975782T3 (es) 2024-07-15
MX2018015960A (es) 2019-03-21
EP3479819B1 (en) 2024-01-24
HRP20240426T1 (hr) 2024-06-21
PE20190448A1 (es) 2019-03-29
JOP20180125A1 (ar) 2019-01-30
LT3479819T (lt) 2024-04-25
MA45562B1 (fr) 2024-05-31
AU2020201249A1 (en) 2020-03-12
EP4338752A2 (en) 2024-03-20
NZ770076A (en) 2025-03-28
EA201892653A1 (ru) 2019-05-31
HUE066142T2 (hu) 2024-07-28
SMT202400143T1 (it) 2024-05-14
MA45562A (fr) 2019-05-08
RS65395B1 (sr) 2024-04-30
AU2020201249B2 (en) 2021-07-15
KR20180097471A (ko) 2018-08-31
KR20180003452A (ko) 2018-01-09
CN109310628A (zh) 2019-02-05
KR102397713B1 (ko) 2022-05-13
DK3479819T3 (da) 2024-04-15
CA3028238C (en) 2024-01-02
BR112018076377A2 (pt) 2019-03-26
IL263630A (en) 2019-01-31
CO2018013689A2 (es) 2019-01-18
WO2018004260A1 (ko) 2018-01-04
ZA201808476B (en) 2020-08-26
CU24561B1 (es) 2022-01-13
PT3479819T (pt) 2024-04-15
JP7405324B2 (ja) 2023-12-26
AU2017287743B2 (en) 2020-01-30
KR20210042052A (ko) 2021-04-16
IL263630B2 (en) 2023-06-01
DK3479819T5 (da) 2024-09-09
EP3479819A4 (en) 2020-02-26
NI201800139A (es) 2019-03-25
NZ748101A (en) 2020-11-27
PL3479819T3 (pl) 2024-07-01
TN2018000443A1 (en) 2020-06-15
CA3028238A1 (en) 2018-01-04
JOP20180125B1 (ar) 2022-09-15
KR102229274B1 (ko) 2021-03-18
JP7082070B2 (ja) 2022-06-07
JP2019525902A (ja) 2019-09-12
PH12018502670B1 (en) 2023-03-24
AU2017287743A1 (en) 2018-11-22
UA122610C2 (uk) 2020-12-10
FI3479819T3 (fi) 2024-04-17
US20240269071A1 (en) 2024-08-15
SG11201811320YA (en) 2019-01-30
TW201806617A (zh) 2018-03-01
SI3479819T1 (sl) 2024-06-28
GEP20217249B (en) 2021-04-26
PH12018502670A1 (en) 2019-10-07
US20210000743A1 (en) 2021-01-07
CU20180154A7 (es) 2019-08-06
MD3479819T2 (ro) 2024-07-31
US11951207B2 (en) 2024-04-09

Similar Documents

Publication Publication Date Title
CL2018003662A1 (es) Formulación farmacéutica líquida estable.
MX382917B (es) Formulaciones de proteínas líquidas que contienen líquidos iónicos.
MX2016006798A (es) Descripcion de medios de presentacion.
BR112017001427A2 (pt) sistema de fornecimento de aerossol
EA201690613A1 (ru) Улучшенные составы на основе аденовирусов
MX391067B (es) Formulaciones de polisacáridos y ácido nucleico que contienen agentes de reducción de viscosidad.
AR098168A1 (es) Formulación estable de insulina glulisina
MX2017016206A (es) DISPOSITIVOS Y Mí‰TODOS PARA ADMINISTRACIí“N Y MEZCLA DE FíRMACO, Y ENTRENAMIENTO DE Tí‰CNICAS APROPIADAS PARA ELLO.
MY180353A (en) Oral composition
PE20150190A1 (es) Formulacion farmaceutica
CL2015002592A1 (es) Método y sistema para grabar contenidos recomendados por medio del uso de agrupadores de contenidos
MX2019003061A (es) Sistema de infusión de gas/líquido en línea con salida de absorción ajustable y capacidad de calibrado automático.
AR110339A1 (es) Bomba y dispositivo de descarga
AR095583A1 (es) Recipiente que tiene un indicador de uso
EA201691132A1 (ru) Инъекционное средство и способ образования депо
CL2011000746A1 (es) Liquido nutricional estable en anaquel comprendiendo beta alanina, proteina y un sistema de carbohidratos en que el liquido nutricional estable en anaquel incluye una relacion molar del sistema de carbohidratos con respecto al aminonitrogeno de lisina de la proteina de menos que aproximadamente 1,0.
MX2015010286A (es) Medicamento con sabor a anis.
MX2016008236A (es) Recipiente y sistema dispensador.
CO2018013179A2 (es) Integración de ubicación en el sistema de correo electrónico
EA201890988A1 (ru) Устройство для хранения и дозирования
BR112017010459A2 (pt) dispositivo para transporte da luz
MY194758A (en) Stable liquid pharmaceutical formulation
CL2016003272A1 (es) Tapón de botella
CL2015003182A1 (es) Un producto nutracéutico modulador del apetito y sensibilizador a la insulina en mamíferos
UA97716U (uk) Лікарський засіб у формі сиропу, що містить фенспіриду гідрохлорид